What does CORUM PHARMA do?

CORUM PHARMA is registered with the CBE as active in: Activiteiten van holdings. Private Limited, started on 15 February 2021, 1 establishment.

What is the address of CORUM PHARMA?

The registered office of CORUM PHARMA is located at Heirweg 144 A, 8710 Wielsbeke.

Is CORUM PHARMA still active?

Yes. According to the CBE (29 September 2026) CORUM PHARMA is active, legal situation “Normale toestand”, started on 15 February 2021.

Is CORUM PHARMA registered on Peppol?

Yes, CORUM PHARMA is registered on the Peppol network with ID 0208:0763652492.

What is the enterprise number of CORUM PHARMA?

The enterprise number of CORUM PHARMA is BE0763652492.

When was CORUM PHARMA founded?

CORUM PHARMA was founded on 15 February 2021.

Who owns CORUM PHARMA?

It owns 100% of Corum Mariakerke itself.

Is CORUM PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 15 February 2021; 4 annual accounts filed, latest fiscal year 2025.

How much profit did CORUM PHARMA make in 2025?

CORUM PHARMA posted a profit after taxes of € 72,475 in financial year 2025.

What is the revenue of CORUM PHARMA?

As a small company, CORUM PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 111,987.

CORUM PHARMA (Private Limited) - Wielsbeke - BE0763652492

Dossier CORUM PHARMA, printed on 29 September 2026 from databakkes.be/en/0763652492/corum-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 7 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

CORUM PHARMA from Wielsbeke, company number BE0763652492, closed financial year 2025 with a result of € 72,475 after tax. For that financial year CORUM PHARMA recorded a gross margin of € 111,987 and equity of € 1.7 million. Compared with financial year 2024, the result moved from € 79,937 to € 72,475. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on October 31, 2025.

What it is worth Growing

€ 1.7 million

▲ 5% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 72,475

▼ 9% vs 2024

Profit after tax over the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 1.6 million.

People and assets in 2025

Vehicles and equipment

€ 39,175

▼ 24% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 6 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 558,221

▼ 15% vs 2024

€ 91,857 is repaid this year. At this pace the long-term loan is gone in ≈ 6 years.

Owed to suppliers

€ 2,253

▼ 23% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 29,500

▼ 12% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Revenue	€ 1,469,000 Revenue 2022: € 1,469,000 First fiscal year in the series	-	-	-
Gross margin	€ 1,416,922 Gross margin 2022: € 1,416,922 First fiscal year in the series	€ 107,825 Gross margin 2023: € 107,825 ▼ 92% vs 2022 (€ 1,416,922) Unfavourable step	€ 118,643 Gross margin 2024: € 118,643 ▲ 10% vs 2023 (€ 107,825) Favourable step	€ 111,987 Gross margin 2025: € 111,987 ▼ 6% vs 2024 (€ 118,643) Unfavourable step	▼ 6%
Profit after taxes	€ 1,385,816 Profit after taxes 2022: € 1,385,816 First fiscal year in the series	€ 82,501 Profit after taxes 2023: € 82,501 ▼ 94% vs 2022 (€ 1,385,816) Unfavourable step	€ 79,937 Profit after taxes 2024: € 79,937 ▼ 3% vs 2023 (€ 82,501) Unfavourable step	€ 72,475 Profit after taxes 2025: € 72,475 ▼ 9% vs 2024 (€ 79,937) Unfavourable step	▼ 9%
Equity	€ 1,435,816 Equity 2022: € 1,435,816 First fiscal year in the series	€ 1,518,317 Equity 2023: € 1,518,317 ▲ 6% vs 2022 (€ 1,435,816) Favourable step	€ 1,598,254 Equity 2024: € 1,598,254 ▲ 5% vs 2023 (€ 1,518,317) Favourable step	€ 1,670,729 Equity 2025: € 1,670,729 ▲ 5% vs 2024 (€ 1,598,254) Favourable step	▲ 5%
Total debts	€ 861,292 Total debts 2022: € 861,292 First fiscal year in the series	€ 785,590 Total debts 2023: € 785,590 ▼ 9% vs 2022 (€ 861,292) Favourable step	€ 770,214 Total debts 2024: € 770,214 ▼ 2% vs 2023 (€ 785,590) Favourable step	€ 664,443 Total debts 2025: € 664,443 ▼ 14% vs 2024 (€ 770,214) Favourable step	▼ 14%
Retained profit	€ 1,385,816 Retained profit 2022: € 1,385,816 First fiscal year in the series	€ 1,468,317 Retained profit 2023: € 1,468,317 ▲ 6% vs 2022 (€ 1,385,816) Favourable step	€ 1,548,254 Retained profit 2024: € 1,548,254 ▲ 5% vs 2023 (€ 1,468,317) Favourable step	€ 1,620,729 Retained profit 2025: € 1,620,729 ▲ 5% vs 2024 (€ 1,548,254) Favourable step	▲ 5%
Bank debt	€ 751,646 Bank debt 2022: € 751,646 First fiscal year in the series	€ 676,392 Bank debt 2023: € 676,392 ▼ 10% vs 2022 (€ 751,646) Favourable step	€ 657,606 Bank debt 2024: € 657,606 ▼ 3% vs 2023 (€ 676,392) Favourable step	€ 558,221 Bank debt 2025: € 558,221 ▼ 15% vs 2024 (€ 657,606) Favourable step	▼ 15%
Balance sheet total	€ 2,297,108 Balance sheet total 2022: € 2,297,108 First fiscal year in the series	€ 2,303,907 Balance sheet total 2023: € 2,303,907 Unchanged (€ 2,297,108) Unchanged	€ 2,368,468 Balance sheet total 2024: € 2,368,468 ▲ 3% vs 2023 (€ 2,303,907) Unchanged	€ 2,335,172 Balance sheet total 2025: € 2,335,172 ▼ 1% vs 2024 (€ 2,368,468) Unchanged	▼ 1%

Key figures of CORUM PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 October 2026.

What happened to CORUM PHARMA?

What happened at CORUM PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Oct 31, 2025 New annual accounts for financial year 2025: profit of € 72,475 (▼ 9% vs 2024). Source: NBB ↗
Feb 15, 2021 New establishment in Wielsbeke. KBO
Feb 15, 2021 Start of the company according to the CBE. KBO

In short

From € 1.4 million profit in 2022 to € 72,475 profit in 2025.

Paid € 84,048 in corporate taxes since 2022.

Best year ever: 2022, with € 1.4 million profit.

Original PDFs at the National Bank ↗

A new publication or filing at CORUM PHARMA? We notify you, reason included.

Follow CORUM PHARMA

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Establishments

Establishment units

Physical locations of this company

Registered office

Heirweg 144 A

8710 Wielsbeke

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0763.652.492

VAT number

BE 0763.652.492

Registered office

Heirweg 144 A, 8710 Wielsbeke

Names & denominations

CORUM PHARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

15 February 2021

Peppol

Active · Active since 4 Jun 2025

Activities · NACE

Activiteiten van holdings

Holdings

View on CBE Public ↗ Annual accounts (NBB) ↗